Pulmonary diseases pose an immense threat to global health. Several nanotherapeutics-
based approaches aimed to tackle pulmonary ailments in recent years. The current …

Asthma is a chronic lung disease affecting millions worldwide. While classically
acknowledged to result from allergen-driven type 2 inflammatory responses leading to IgE …

Lung fibrosis, one of the major post‐COVID complications, is a progressive and ultimately
fatal disease without a cure. Here, an organ‐and disease‐specific in vitro mini‐lung fibrosis …

As post‐COVID complications, chronic respiratory diseases are one of the foremost causes
of mortality. The quest for a cure for this recent global challenge underlines that the lack of …

Cystic fibrosis (CF) is a muco-obstructive lung disease where inflammatory responses due to
chronic infection result in the accumulation of neutrophil extracellular traps (NETs) in the …

Bioavailability assessment in the development phase of a drug product is vital to reveal the
disadvantageous properties of the substance and the possible technological interventions …

Human lung tissue models range from simple monolayer cultures to more advanced three-
dimensional co-cultures. Each model system can address the interactions of different types …

Inflammatory bowel disease (IBD) encompasses a set of chronic inflammatory conditions,
namely Crohn's disease and ulcerative colitis. Despite all advances in the management of …

Nanomedicine has a great potential to revolutionize the therapeutic landscape. However, up-
to-date results obtained from in vitro experiments predict the in vivo performance of …

In vitro dissolution and permeability testing aid the simulation of the in vivo behavior of
inhalation drug products. Although the regulatory bodies have specific guidelines for the …